Faculty Affairs: Faculty Interests Database
Walter K Kraft

Pharmacology & Experimental Therapeutics
Associate Professor
Department of Pharmacology and Experimental Therapeutics

Secondardy Appointments
Department of Medicine
Department of Surgery
Appointed: 2001

Director, Clinical Research Unit

Associate Director, Office of Human Research

Faculty, College of Biomedical Sciences

Vice Chair
Institutional Review Board Committee
Mailing Address Contact Information
132 S. 10th St., 1170 Main Building
Philadelphia, Pennsylvania 19107-5244
United States
walter.kraft@jefferson.edu
Qualifications
MD University of Pittsburgh, 1995
MS (Pharmacology), Thomas Jefferson University, 2006

Board Certifications:
Internal Medicine 1998, (Recertification 2008)
Clinical Pharmacology 2003

Fellow, American College of Physicians

American Board of Clinical Pharmacology, Governing Board Member

Association of Clinical Pharmacology Units, Chair 2013 Annual Meeting

American College of Clinical Pharmacology, Co-Chair Annual Meeting 2014

United States Pharmacopeia, Convention Member

Associate Editor, Clinical Therapeutic Research
Expertise and Research Interests
Research Interests:
Phase one clinical trials
Treatment of neonatal abstinence syndrome
Clinical Pharmacology

Clinical Interests:
Anticoagulation
Hospital-based vascular medicine consultation
Industrial Relevance
Dr. Kraft has expertise in the clinical, regulatory, and managerial aspects of Phase 1 drug development.
Publications
  • Hastie AT, Kraft WK, Nyce KE, Zangrilli JG, Fish JP, Peters SP. Kinetics of Airway Epithelial Cell Proliferation And Stimulation of Collagen After Segmental Allergen Challenge. American Journal of Respiratory and Critical Care Medicine. 2002; 165:266-272
  • Blum RA, Majumdar A, McCrea J, Busillo J, Orlowski LH, Panebianco D, Hesney M, Petty KJ, Goldberg MR, Murphy MG, Gottesdiener KM, Hustad CM, Lates C, Kraft WK, VanBuren S, Waldman SA , Greenberg HE. Effects of Aprepitant on the Pharmacokinetics of Ondansetron and Granisetron in Healthy Subjects. Clinical Therapeutics. 2003; 25:1407-19
  • Burke J, Kraft WK, Greenberg HE, Gleave M, Pitari GM, VanBuren S, Wagner J, Waldman SA. Relationship of Arachidonic Acid Concentration to Cyclooxygenase-Dependent Human Platelet Aggregation. Journal of Clinical Pharmacology. 2003; 43:983-989
  • Kraft WK, Steiger B, Beussink D, Quiring JN, Fitzgerald N, Greenberg HE, Waldman SA. The Pharmacokinetics of Nebulized Nanocrystal Budesonide Suspension in Healthy Volunteers. Journal of Clinical Pharmacology. 2004; 44:67-72
  • Kraft WK, McCrea JB, Winchell GA, Carides A, Lowry R, Woolf EJ, Kusma SE, Deutsch PJ, Greenberg HE, Waldman SA. Indinavir and Rifabutin Drug Interactions in Healthy Volunteers. Journal of Clinical Pharmacology. 2004; 44:305-13
  • Filicko J, Kakhniashvili I, Kraft WK, Flomenberg N. Heterogeneous Clearance of Anti-Thymocyte Globulin (ATG) Following CD34+ Selected Allogeneic Hematopoietic Progenitor Cell Transplantation (HPCT). Biology of Blood and Bone Marrow Transplantation. 2005, 11(8):609-18
  • Patel T, Pequignot E, Parker SH, Leavit MC, Greenberg HE, Kraft WK. Transgenic avian derived glycosylated recombinant human interferon alpha-2b (AVI-005): an open label, controlled, single dose study in healthy subjects. International Journal of Clinical Pharmacology and Therapeutics. 2007;45(3):161-68
  • Gong L, Greenberg HE, Perhach JL, Waldman SA, Kraft WK. The Pharmacokinetics of Taurolidine Metabolites in Healthy Volunteers. Journal of Clinical Pharmacology. 2007;47 697-703
  • Majumdar AK, Yan KX, Selverian DV, Barlas S, Constanzer M, Dru J, McCrea JB, Ahmed T, Frick GS, Kraft WK, Petty KJ, Greenberg HE. Effect of aprepitant on the pharmacokinetics of IV midazolam. Journal of Clinical Pharmacology. 2007;47 744-750
  • Internet Video Highlighting the Drug Development Process (Clinical Trials), available at http://www.innovation.org/index.cfm/InsideDrugDiscovery
  • Ghanim AJ, Daskalakis C, Eschelman EJ, Kraft WK. A Five-Year Retrospective, Comparison Review of Survival in Neurosurgical Patients Diagnosed with Venous Thromboembolism and Treated with Either Inferior Vena Cava Filters or Anticoagulants. Journal of Thrombosis and Thrombolysis. 2007; 24(3):247-54
  • LaRusso J, Waldman SA, Kraft WK. Aprepitant For The Prevention Of Nausea And Vomiting Associated With Chemotherapy And Postoperative Recovery. Expert Review in Clinical Pharmacology. 2008; 1(1),27-37
  • Kraft WK , Waldman SA. Bridging the Therapeutic Continuum of Drug Development, Regulation and Use. Expert Review in Clinical Pharmacology. 2008; 1(1),1-3
  • Mejia A, Kraft WK,. "Peptic Ulcer Disease and Reflux', in Waldman SE, Terzic A, Eds., Pharmacology and Therapeutics: Principles to Practice , 1st. Ed., Elsevier; 2008
  • Kraft WK, Leone F. "Asthma and COPD", in Waldman SE, Terzic A, Eds., Pharmacology and Therapeutics: Principles to Practice , 1st. Ed., Elsevier; 2008
  • Kraft WK, Gibson E, Dysart K, Damle V, LaRusso J, Greenspan J, Moody D, Kaltenbach K, Ehrlich M. Sublingual Buprenorphine for Treatment of the Neonatal Abstinence Syndrome: A Randomized Trial. Pediatrics 2008; 122:e601-7
  • Kraft WK, Desimone DC. "Asthma, Chronic Treatment" In: Ebell MH, ed. Essential Evidence Plus. 1st ed. Hoboken, NJ: John Wiley and Sons.
  • Kraft WK. "Neonatal Abstinence Syndrome" In: Ebell MH, ed. Essential Evidence Plus. 1st ed. Hoboken, NJ: John Wiley and Sons.
  • Kraft WK, Mejia A. Acid Peptic Diseases: Pharmacological Approach To Treatment. Expert Review in Clinical Pharmacology 2009; 2(3):295-314
  • Varki R, Pequignot E, Leavitt MC, Ferber A, Kraft WK. A Glycosylated Recombinant Human Granulocyte Colony Stimulating Factor Produced in a Novel Protein Production System (AVI-014) in Healthy Subjects: A First-in Human, Single Dose, Controlled Study. BMC Clinical Pharmacology 2009, 9(1):2 http://jdc.jefferson.edu/petfp/3
  • Loboda A*, Kraft WK*, Joseph J, Fine B, Nebozhyn M, Zhang C, He Y, Yang X, Wright C, Morris M, Chalikonda I, Ferguson M, Dai H, Emilsson V, Schadt E, Greenberg HE, Lum PY. Diurnal variation in human adipose and its link to metabolic diseases and mTOR signaling. BMC Medical Genomics 2009, 2:7 [PMID 19203388] *contributed equally to this manuscript
  • Waldman SA, Kraft WK, Nelson T, Terzic A. Experimental Therapeutics: A Paradigm for Personalized Medicine. Clinical and Translational Science 2009; 2(6): 436438. [PMID: 20443936]
  • Kim DH, Daskalakis C, Whellan DJ, Whitman IR, Hohmann S, Medvedev S, Kraft WK. Safety of Selective Serotonin Reuptake Inhibitor in Adults Undergoing Coronary Artery Bypass Grafting. American Journal of Cardiology 2009; 103:1391-5 [PMID 19427434]
  • Lai E, Schwartz JI, Dallob A, Jumes P, Liu F, Kraft WK, Royalty J, Chodakewitz J, Sisk CM, Radziszewski W, Wagner JA. Effects of Extended Release Niacin/Laropiprant, Laropiprant, Extended Release Niacin, and Placebo on Platelet Aggregation and Bleeding Time in Healthy Subjects. Platelets 2010;21(3):191-8 [PMID: 20163197]
  • Vasu TS, Doghramji K, Cavallazzi R, Grewal R, Hiraini A, Leiby B, Markov D, Reiter D, Kraft WK, Witkowski T. Obstructive Sleep Apnea Syndrome and Postoperative Complications: Clinical Utility of the STOP-BANG Questionnaire. Archives of Otolaryngology - Head & Neck Surgery. 2010;136(10):1020-1024 [PMID: 20956751]
  • Stoch AS, Gargano C, Valentine J, Braun MP, Murphy MP, Fedgchin M, Majumdar A, Pequignot E, Gottesdiener KM, Petty KJ, Panebianco D, Dean D, Evans JK, Kraft WK, Greenberg HE. Double-Blind Crossover Study to Assess Potential Differences in Cytochrome P450 3A4 Activity in Healthy Subjects Receiving Ondansetron Plus Dexamethasone, With and Without Aprepitant. Cancer Chemotherapy and Pharmacology. 2010 Aug 24. Epub ahead of print [PMID: 20734049]
  • Kraft WK, Dysart K, Greenspan J, Gibson E, Kaltenbach K, Ehrlich M. Revised Dose Schema of Sublingual Buprenorphine in the Treatment of the Neonatal Opioid Abstinence Syndrome. Addiction. 2010 Oct 6. Epub ahead of print [PMID: 20925688] http://jdc.jefferson.edu/petfp/7
  • Dallob A, Luo WL Mabalot J, Ratcliffe L, Johnson-Levonas A, Schwartz JI, Dishy V, Kraft WK, de Hoon JN, Van Hecken A, de Lepeleire I, Radziszewski W, Wagner JA, Lai E. The Effects of Laropiprant, a Selective Prostaglandin D2 Receptor 1 Antagonist, on the Antiplatelet Activity of Clopidogrel or Aspirin. Platelets. 2011; 22(7):495-503. [PMID: 21526889]
  • http://jdc.jefferson.edu/petfp/14/
  • Henwood PC, Kennedy KM, Thomson L, Galanis T, Tzanis G, Merli GJ, Kraft WK. The Incidence of Deep Vein Thrombosis Detected by Routine Surveillance Ultrasound in Neurosurgery Patients Receiving Dual Modality Prophylaxis. Journal of Thrombosis and Thrombolysis. 2011; 32(2):209-14. [PMID: 21505787] http://jdc.jefferson.edu/petfp/25
  • Hiraini A, Cavallazzi R, Vasu TS, Pachinburavan M, Kraft WK, Leiby B, Desimone J, Squires KE, Weibel S, Kane GK. Prevalence of Obstructive Lung Disease in HIV population: A Cross Sectional Study. Respiratory Medicine. 2011; 105(11):1655-61. [PMID: 21703841]
  • Reitman M, Dishy V, Moreau A, Denney W, Liu, C, Kraft WK, Mejia A, Matson M, Stoch A, Wagner J, Lai E. Pharmacokinetics and Pharmacodynamics of MK-5046, a Bombesin Receptor Subtype-3 (BRS-3) Agonist, in Healthy Subjects. Journal of Clinical Pharmacology. 2012;52 1306-1316 [PMID:22162541]
  • Anagnostis EA, Sadaka RE, Sailor LA, Moody DE, Dysart KC, Kraft WK. Formulation of Buprenorphine for Sublingual Use in Neonates. Journal of Pediatric Pharmacology & Therapeutics. 2011;16(4):281-4. [PMID: 22768012] http://jdc.jefferson.edu/petfp/38/
  • Cavallazzi R, Awe OO, Vasu TS, Hiraini A, Vaid U, Leiby B, Kraft WK, Kane GK. MELD Score for Predicting Outcome In Critically Ill Patients with Liver Cirrhosis. Journal of Critical Care. 2012; 27(4):424.e1-6 [PMID: 22227088]
  • Pasquinelli C, McPhee F, Eley T, Villegas C, Sandy K, Wendelburg P,. Persson A, Hernandez D, Sheaffer A, Scola P, Marbury T, Lawitz E, Goldwater R, Rodriguez-Torres M, DeMicco M, Wright D, Charlton M, Kraft WK, Lopez-Talavera J, Grasela DM. Single and Multiple Ascending Dose Studies of the NS3 Protease Inhibitor Asunaprevir in Subjects With or Without Chronic Hepatitis C. Antimicrobial Agents and Chemotherapy. 2012; 56(4):1838-44. [PMID: 22290978]
  • Stroh M, Palcza J, McCrea J, Marsilio S, Breidinger S, Panebianco D, Johnson-Levonas A, Kraft WK, Orford K, Murphy G, Agrawal N, Trucksis M, Wagner JA. The Effect of Multiple Doses of Rifampin and Ketoconazole on the Single Dose Pharmacokinetics of Ridaforolimus. Cancer Chemotherapy and Pharmacology. 2012 Jan 31 Epub ahead of print [PMID: 22290273]
  • Kosoglou T, Kraft WK, Kumar B, Statkevich P, Xuan F, Ma L, Jennings LK, Schiller JE, Langdon RB, Cutler DL. Pharmacokinetics and Pharmacodynamics of the Novel PAR-1 Antagonist Vorapaxar in patients with End-Stage Renal Disease. The European Journal of Clinical Pharmacology. 2012; 68(7):1049-56 [PMID: 22315147]
  • Pavri BD, Greenberg HE, Kraft WK, Lazarus N, Lynch JJ, Salata J, Bilodeau M, Regan CP. Stump G, Fan L, Larson P, Mehta A, Wagner JA, Gutstein DE, Bloomfield D. MK-0448, a Specific Kv1.5 Inhibitor, Safety, Pharmacokinetics and Pharmacodynamic Electrophysiology Results in Experimental Animal Models and Humans. Circulation: Arrhythmias & Electrophysiology. 2012; 5(6):1193-201 [PMID: 23060423] http://jdc.jefferson.edu/petfp/40
  • Halegoua-De Marzio D, Kraft WK, Daskalakis C, Ying X, Hawke RL, Navarro VJ. Limited Sampling Estimates of Epigallocatechin Gallate Exposures in Cirrhotic and Non-cirrhotic Hepatitis C Subjects After Single Oral Doses of Green Tea Extract. Clinical Therapeutics. 2012; 34:2279-2285 [PMID 23153661] http://jdc.jefferson.edu/gastro_hepfp/17/
  • Vaid U, Singer E, Marhefka GD, Kraft WK, Baram M. Poor Positive Predictive Value of McConnells Sign on Transthoracic Echocardiography for Diagnosis of Acute Pulmonary Embolism. Hospital Practice. 2013;3(41)23-7 [PMID 23948618] http://jdc.jefferson.edu/petfp/46
  • Lawitz E, Sulkowski M, Jacobson I, Faruqi S, Kraft WK, Maliakkal B, Al-Ibrahim M, Ghalib R, Gordon S, Kwo P, Rockstroh J, Panorchan P, Miller M, Caro L, Barnard R, Hwang PM, Gress J, Quirk E, Mobashery N. Safety, Anitiviral and PK activity of Vaniprevir, a Hepatitis C Virus NS3/4A Protease Inhibitor, in Patients with HCV Genotype 1 Infection [Accepted, Antiviral Research]
  • Kupetsky-Rincon E, Kraft WK. Healthy Volunteer Registries and Ethical Research Principles. Clinical Pharmacology and Therapeutics. 2012; 91(6):965-8. [PMID: 22609908] http://jdc.jefferson.edu/petfp/36
  • Kraft WK, van den Anker JN. Pharmacologic Management of the Opioid Neonatal Abstinence Syndrome. Pediatric Clinics of North America. 2012; 59(5):1147-65 [PMID: 23036249] http://jdc.jefferson.edu/petfp/39
  • Okabe T, Kanzaria M, Rincon F, Kraft WK. Cardiac Abnormalities after Subarachnoid Hemorrhage: The Role of Cardiovascular Protection to Improve Clinical Outcome. Neurocrit Care. 2012 Dec 13. [Epub ahead of print] [PMID: 23238984]

Last Updated by Walter Kraft: Friday, August 23, 2013 10:30:33 AM

Back to top


Click to leave feedback
feedback